Europe’s regulatory system for medicines can be used more effectively

22 September 2014
eu-european-union-flag

A new report from Escher, the independent TI Pharma platform for regulatory innovation, shows that the current regulatory system for medicines in the Europe Union could be used in more efficient and effective ways.

Andre Broekmans, Escher’s chairman, explained: "Overall, the EU regulatory system operates well, however important recent changes had not been evaluated until now. One of our report's conclusions is that pathways originally intended to bring important new medicines to market faster are not being used in the right way. We are therefore missing opportunities to make medicines available to patients earlier."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical